Dr Felip discusses the most recent efficacy data from ASCO 2021 on the use of MET inhibitors in NSCLC1/3 Next Interview
Dr Heist discusses the most recent data from ASCO 2021 on MET testing in NSCLC within the context of current research and recommendations.2/3 Next Interview
Dr Seto discusses the most recent safety data from ASCO 2021 on the use of MET inhibitors in NSCLC3/3 Take CME Test
Overview & Learning Objectives
In this activity, three experts explore the evolving landscape of MET inhibitors in NSCLC, share the latest efficacy and safety data from ASCO 2021 and highlight the importance of testing for METex14 in the clinic.
This activity has been jointly provided by Oakstone and touchIME for touchONCOLOGY. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians.
This activity has been designed to meet the educational needs of oncologists and respirologists involved in the management of non-small cell lung cancer.
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest have been mitigated. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relationships with ineligible entities.
Dr Enriqueta Felip discloses: Advisory board fees from Amgen, AstraZeneca, Bayer, Beigene, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Merck Serono, Peptomyc, Pfizer, Puma, Regeneron, Sanofi, Syneos Health and Takeda. Invited speaker fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Janssen, Merck Sharp & Dohme, Merck Serono and Pfizer.
Dr Rebecca S Heist discloses: Consulting honoraria from Apollomics, Boehringer Ingelheim, Daichii Sankyo, EMD Serono, Novartis, and Takeda. Research funding (to institution, not to self) from Agios, AbbVie, Corvus, Daiichi Sankyo, Eli Lilly, Exelixis, Genentech Roche, Mirati, Novartis, and Turning Point.
Dr Takashi Seto discloses: Consulting honoraria from AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Covidien Japan, Daiichi Sankyo, Eli Lilly Japan, Kyowa Hakko Kirin, Mochida Pharmaceutical, MSD, Nippon Boehringer Ingelheim, Novartis Pharma, Ono Pharmaceutical, Pfizer Japan, Taiho Pharmaceutical and Takeda Pharmaceutical. Research funding from Abbvie, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, Kissei Pharmaceutical, LOXO Oncology, Merck Sharp & Dohme, Novartis Pharma, Pfizer Japan and Takeda Pharmaceutical.
Walter Murray Yarbrough, MD, FACP has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and touchIME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
Date of original release: 29 July 2021. Date credits expire: 29 July 2022.
After watching this activity, participants should be better able to:
- Recall the latest efficacy data from MET-inhibitor clinical trials in NSCLC
- Describe diagnostic methods for the identification of MET exon 14 skipping mutations and MET amplification
- Discuss practical adverse event management with MET inhibitors in the clinic